MetaMacNiche · Unravelling the cell-cell circuits underlying the functional reprogramming of KCs and TAMs during liver metastasis
Horizon Europe — Marie Skłodowska-Curie Actions
- Duration
- 2023-11-01 → 2025-10-31
- EU contribution
- €175,920
- Participants
- 1
- Scheme
- HORIZON-TMA-MSCA-PF-EF
Lines connect the coordinator with its partners.
Results in brief
Unravelling the cell-cell circuits underlying the functional reprogramming of KCs and TAMs during liver metastasis
The liver is a highly vascularized organ due to its major role in filtering blood. Because of this, the liver is also one of the main site of metastatic dissemination for several cancers. The most common one is colorectal cancer, with up to 50% of patients developing liver metastases. The primary treatment for liver metastasis is surgery but, if metastases are too spread, surgery is not an option anymore. The 21st century has marked a boomed in immunotherapy, especially in cancer. However, previous research have highlighted that metastatic dissemination to the liver impairs systemic immune responses, making patients less responsive to immunotherapy. Macrophages are the most abundant immune population in many cancers. Kupffer cells are the resident macrophages of the liver are the first cells to interact with metastatic cells due to their location in the liver sinusoids. Additionally, monocyte-derived macrophages are also rapidly recruited as metastatic cells are spreading to the liver, and will constitute the tumor-associated macrophages (TAMs). The distinct role of Kupffer cells and TAMs in metastatic spreading and anti-cancer immune response have been studied in the past but showed conflicting results. Macrophages in cancer do not form a homogenous cell populations and can be wired to perform various functions, either promoting or inhibiting anti-cancer immunity. Our group, and other have shown that macrophage function is dictated not only by intrinsic factor, but also by signals delivered by their surrounding cells (ie fibroblasts, endothelial cells, cancer cells…), defining the macrophage niche. Using unique tracking tools developed in our lab, as well as cutting-edge omics and spatial technologies, this project aims at deciphering the cross-talk between macrophages and their niche, the consequences on macrophage polarization and immunotherapy response, as well as identifying novel therapeutic targets that can modulate tumor macrophage activation.
Data: CORDIS, © European Union
Project objective
The liver is one the most common metastatic sites for several cancers. Unfortunately, liver metastasis patients show a particularly low response to immunotherapy. One of the main immune cells populating liver metastases are macrophages. These cells have been shown to play a key role in the regulation of anti-tumor immune responses, including response to immunotherapy. However, we still lack the capacity to modulate macrophage activity during liver metastasis, because we do not yet understand their functional diversity and do not know the molecular signals that drive the pro-tumoral activity of macrophages during liver metastasis. The host lab has recently reported a major role for cell-cell interactions within the microenvironmental niche in the development and functional specialization of liver macrophages. My preliminary data indicate that liver metastasis is accompanied with the expansion of both liver-resident Kupffer cells (KCs) and monocyte-derived tumor-associated macrophages (TAMs). Single-cell analysis in mouse and human revealed that TAMs recruited during metastasis are heterogeneous and transcriptomically different from KCs, suggesting a distinct functional specialization. The molecular pathways involved in the functional reprogramming of KCs and TAMs and their relative contribution to tumor growth, remain poorly understood. In this MetaMacNiche project, I will use a combination of cutting-edge spatial multiomic technologies, intravital microscopy, and an in vivo CRISPR screen to investigate the role of KCs and TAMs in liver metastasis. Through a combination of in silico predictions and high-throughput in vivo validations, I will identify the key cell-cell interactions involved in the functional reprogramming of KCs and TAMs during liver metastasis. Finally, I aim to perform preclinical studies to assess whether we can boost the responsiveness to immunotherapy by modulating macrophage activity during liver metastasis.
Original text from CORDIS.
Participants
- VIB VZW · ZWIJNAARDE - GENTCoordinatorBelgium
Links
- View on CORDIS
- DOI: 10.3030/101109361
- https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e50ef8ece5&appId=PPGMS
- https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e5287b4c97&appId=PPGMS
Data: CORDIS, © European Union
